HK Stock Market Move | Central European electric vehicle negotiations make significant progress BYD COMPANY (01211) rose more than 4% XPENG-W (09868) rose more than 3%
Automobile stocks rose across the board in the morning session, as of press time, BYD Company Ltd. (01211) rose by 4.13% to HKD 99.65, while XPeng Inc. (09868) rose by 3.55% to HKD 83.2.
Stocks of car companies rose in the early morning, with BYD COMPANY (01211) up 4.13% to HK$99.65, XPENG-W (09868) up 3.55% to HK$83.2, LEAPMOTOR (09863) up 2.91% to HK$48.8, and LI AUTO-W (02015) up 2.54% to HK$66.7.
In terms of news, the Ministry of Commerce announced on January 12th that negotiations between China and the EU on the electric car case have progressed. The EU will release a "Guidance Document on Submitting Price Commitment Applications," adhere to the non-discrimination principle, and evaluate each price commitment application objectively and fairly in accordance with WTO rules. The China Machinery Industry Association believes that properly addressing the EU's anti-subsidy case against Chinese electric cars is a common expectation for the electric car industry in China and Europe. It will help promote the security and stability of the supply chain in the China-Europe related industrial chain, maintain the overall situation of China-Europe economic and trade cooperation, and uphold the international trade order based on rules.
Related Articles
.png)
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.
.png)
HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


